东亚药业(605177) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥190,921,213.83, a decrease of 45.85% compared to ¥352,582,674.10 in the same period last year[4] - The net profit attributable to shareholders was -¥6,919,576.54, representing a decline of 128.78% from ¥24,039,198.04 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥10,505,893.27, down 151.56% from ¥20,376,579.89 in the previous year[4] - The basic earnings per share were -¥0.06, a decrease of 128.57% compared to ¥0.21 in the same period last year[5] - The diluted earnings per share were -¥0.05, down 131.25% from ¥0.16 year-on-year[5] - The weighted average return on equity was -0.37%, a decrease of 1.56 percentage points from 1.19% at the end of the previous year[5] - Total operating revenue for Q1 2025 was ¥190,921,213.83, a decrease of 46% compared to ¥352,582,674.10 in Q1 2024[17] - Net profit for Q1 2025 was a loss of ¥6,944,904.17, compared to a profit of ¥24,039,198.04 in Q1 2024, representing a significant decline[19] - Basic earnings per share for Q1 2025 were -¥0.06, compared to ¥0.21 in Q1 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥134,527,926.86, compared to -¥97,089,771.88 in the same period last year, indicating a worsening cash flow situation[4] - Cash inflow from operating activities in Q1 2025 was ¥161,648,356.28, down from ¥187,462,985.54 in Q1 2024[20] - Cash paid for purchasing goods and services in Q1 2025 was ¥211,678,832.80, an increase from ¥190,711,887.65 in Q1 2024[20] - The total cash and cash equivalents at the end of the period decreased to $238.29 million from $665.96 million, reflecting a significant reduction in liquidity[21] - The company experienced a cash outflow of $250.04 million during the period, compared to a smaller outflow of $35.00 million previously, indicating a worsening cash position[21] - Cash outflow for investment activities was $245.04 million, up from $138.97 million, suggesting aggressive investment strategies[21] - The net cash flow from operating activities was -$134.53 million, compared to -$97.09 million in the previous period, indicating a decline in operational cash generation[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,485,834,743.46, a decrease of 1.99% from ¥3,556,607,162.74 at the end of the previous year[5] - The company's current assets totaled RMB 1,426,806,317.93, down from RMB 1,528,952,567.49, indicating a decrease of about 7%[14] - Cash and cash equivalents decreased significantly from RMB 513,176,766.27 to RMB 253,575,131.72, representing a decline of approximately 51%[13] - Total liabilities decreased from RMB 1,681,871,175.04 to RMB 1,614,992,526.30, reflecting a decline of about 4%[15] - The company's equity attributable to shareholders decreased from RMB 1,874,615,395.36 to RMB 1,870,746,952.45, a slight decline of around 0.2%[15] - The total liabilities and equity amounted to ¥3,485,834,743.46 as of the end of Q1 2025, a decrease from ¥3,556,607,162.74 in the previous year[16] Investments and Expenses - Research and development expenses for Q1 2025 were ¥23,009,005.87, up from ¥19,280,144.23 in Q1 2024, indicating increased investment in innovation[17] - The company reported a credit impairment loss of ¥3,330,066.74 in Q1 2025, compared to a gain of ¥4,848,150.68 in Q1 2024[18] - The company experienced a significant increase in management expenses, which rose to ¥43,208,414.35 in Q1 2025 from ¥40,657,303.31 in Q1 2024[17] Government Support and Market Conditions - The company received government subsidies amounting to ¥3,167,874.39, which were closely related to its normal operations[6] - The decrease in revenue was primarily due to reduced order demand from downstream customers for β-lactam antibiotics[7]